<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764243</url>
  </required_header>
  <id_info>
    <org_study_id>P211-03</org_study_id>
    <nct_id>NCT01764243</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MT-4666</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy as assessed by the
      Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of
      MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate
      Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ADAS-cog-13</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Alzheimers Disease Assessment Scale-cognitive subscale 11-item (ADAS-cog-11)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mini-Mental State Examination (MMSE)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Modified Crichton Scale</measure>
    <time_frame>Baseline and Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>MT-4666 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-4666 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-4666</intervention_name>
    <description>low dose, high dose</description>
    <arm_group_label>MT-4666 Low Dose</arm_group_label>
    <arm_group_label>MT-4666 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable Alzheimer's disease consistent with National Institute of Neurological and
             Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related
             Disorders Association (ADRDA) criteria

          -  MMSE score of 10 to 24 inclusive at screening and at Day 1, and CDR-SB score of ≥ 2 at
             screening

          -  Modified Hachinski Ischemic Score (mHIS) ≤ 4 at screening

          -  Caregiver available; caregiver sees subject at least four days (at least 12 hours)
             each week

          -  Subject living at home; if living at senior residential setting, or an institutional
             setting, subject with caregiver indicated above is available

        Exclusion Criteria:

          -  Inability to perform cognitive tests (ADAS-cog-13 and MMSE) at screening and at Day 1

          -  Diagnosis of any other disease which may cause dementia

          -  MRI or CT scan within 6 months before screening, with findings inconsistent with the
             diagnosis of Probable AD

          -  Diagnosis of major depressive disorder as defined by Diagnostic and Statistical Manual
             of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within last five years

          -  History of or current diagnosis of any psychosis

          -  History of myocardial infarction or unstable angina within six months before screening

          -  History of cerebrovascular disorder within 18 months before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Nakamura, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kagawa University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akira Homma, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tokyo Dementia Care Research and Training Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shun Shimohama, M.D., D. Med. SC</last_name>
    <role>Study Director</role>
    <affiliation>Sapporo Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Nicotinic Acetylcholine Receptor Agonist</keyword>
  <keyword>Cognitive function</keyword>
  <keyword>Dementia</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

